What type of psychotropic drugs does DaliRasheng (Keweike) belong to and its safety analysis

Daridorexant (Daridorexant) is a new mechanism of insomnia treatment drug. It is a dual orexin receptor antagonist (DORA, Dual Orexin Receptor Antagonist) and is not a traditional benzodiazepine sedative-hypnotic drug. It blocks orexin 1 type and 2 type receptors (OX1R and OX2R), inhibiting neural signals in the awake state, thereby helping patients fall asleep naturally and stay awake the next day, making it less likely to produce the "hangover effect." Compared with traditional sleeping pills, the effect of DaliRasen on sleep structure is closer to physiological sleep, and it is especially outstanding in maintaining sleep.

In terms of drug classification, DaliRazen is not classified as a benzodiazepine or barbiturate psychotropic drug in the United States, but is approved as a new central nervous system-acting drug. It has not yet been included in the strict control catalog of the "Regulations on the Administration of Narcotic Drugs and Psychotropic Drugs" in our country, but it is listed as a prescription drug in some countries and regions and must be used with a doctor's prescription. Because its mechanism of action is more precise and has less impact on cognitive function and attention the next day, it is clinically considered a relatively safe and low-dependency sleep aid.

In terms of safety, clinical studies show that DaliRazo is well tolerated. The most common adverse reactions include mild headache, drowsiness, fatigue and occasional dream changes. Most symptoms are short-lived and can be relieved by themselves. Unlike benzodiazepines, Dalitrazolin does not significantly depress the central respiratory system and is not likely to cause tachyphylaxis or drug dependence. In addition, it has relatively little impact on next-day function in elderly patients, giving it certain advantages in long-term use.

However, DaliRasen still needs to be used under the guidance of a doctor, especially for patients with depression, anxiety, sleep apnea syndrome or long-term use of sedative drugs. Individual risks need to be assessed and the combined use of drugs that may cause sedation superposition should be avoided. At the same time, drivers and personnel operating precision instruments should avoid high-risk activities after taking medication to prevent safety risks caused by reduced concentration. Overall, as a new type of DORA drug, DaliRazen has both efficacy and safety in the treatment of insomnia and has broad clinical application prospects.

Reference materials:https://www.drugs.com/